https://www.selleckchem.com/pr....oducts/telratolimod.
39-0.89; p=0.01). In patients without ESR1 mutations detected, PFS was 4.8 months (95%CI,3.7-6.2) on exemestane and 4.1 months (95%CI,3.6-5.5) on fulvestrant (HR=1.05, 95%CI,0.81-1.37; p=0.69). There was an interaction between ESR1 mutation and treatment (p=0.02). Patients with ESR1 mutation detected had one-year overall survival of 62% (95%CI,45%-75%) on exemestane and 80% (95%CI,68%-87%) on fulvestrant (p=0.04, restricted mean survival analysis). Patients without ESR1 mutations detected has one-year overall survival of 79% (95%CI
Like
Comment
Share
